Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 12/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20266333 | 0.88 | GLP1R (0.44) | GLP1RACSS2 | |
| SCHEMBL31159736 | 0.79 | GLP1R (0.45) | GLP1RACSS2 | |
| SCHEMBL20266537 | 0.79 | GLP1R (0.45) | GLP1RACSS2 | |
| Hydrochloric Acid SCHEMBL28910361 | 0.78 | GLP1R (0.44) | GLP1RACSS2 | |
| Hydrochloric Acid SCHEMBL30269640 | 0.78 | GLP1R (0.44) | GLP1RACSS2 | |
| SCHEMBL28860552 | 0.77 | AGTR1 (0.50) | AGTR1AGTR2ACSS2PPARG | |
| SCHEMBL30740795 | 0.76 | ACSS2 (0.46) | GLP1RACSS2PPARG | |
| SCHEMBL29826815 | 0.76 | ACSS2 (0.46) | GLP1RACSS2PPARG | |
| SCHEMBL29281094 | 0.75 | LGALS8 (0.55) | LGALS8PPARG | |
| SCHEMBL24792073 | 0.74 | GLP1R (0.60) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-02-01 | — | — | US | disclosed |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3555064-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11512070-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-3555064-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20210047298-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10851081-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200255406-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2020-08-13 | — | — | US | disclosed |
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3555064-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109607-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-11512070-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 992/4885AGTR2 1332/4885 |
| US-10851081-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-20210047298-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-20200255406-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885AGTR1 607/4885AGTR2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.